Financial results: Bioxyne; Rua Bioscience; Bod Science; Avecho; Wellnex Life; MGC Pharma; Cannasouth by Steve Jones March 7, 2024March 7, 2024 Bioxyne was hit with an impairment charge of A$11.5 million in the first half of FY24 […]
Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024July 11, 2024
Financial results: Avecho; Wellnex; Zelira; Emyria; Botanix; MGC Pharma; AusCann; Epsilon; Melodiol; Bioxyne by Martin Lane and Steve Jones September 4, 2023April 30, 2024
Avecho raises another A$6m to fund trial as firm enters ‘defining chapter’ by Steve Jones August 28, 2023April 30, 2024
Avecho looks to Authorised Prescribers to find optimal dose for new fast-onset THC gummies by Steve Jones August 9, 2023August 21, 2023
Avecho completes development of fast-onset CBD gummy product by Martin Lane June 14, 2023April 30, 2024
Avecho plots A$11m capital raise to underpin CBD clinical trial by Steve Jones April 3, 2023April 30, 2024
Company news: Emyria; Ecofibre; Avecho; Medlab; MGC Pharma; AusCann; Botanix; Incannex; GFI by Martin Lane and Steve Jones November 1, 2022April 29, 2024
Modern medicine: can the dominance of oil and flower be challenged? by Steve Jones October 6, 2022April 29, 2024
Avecho ‘adamant’ that S3 insomnia trial must be accepted overseas by Steve Jones May 4, 2022April 29, 2024
